LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS: FINAL RESULTS FROM THE BALANCE-EXTEND OPEN-LABEL EXTENSION STUDY

被引：0
|
作者：
Kivitz, A. [1 ]
Wells, A. F. [2 ]
Vargas, J. Ignacio [3 ]
Baraf, H. S. B. [4 ,5 ]
Rischmueller, M. [6 ,7 ,8 ]
Klaff, J. [9 ]
Khan, N. [9 ]
Li, Y. [9 ]
Carter, K. [9 ]
Friedman, A. [9 ]
Durez, P. [10 ]
机构：
[1] Altoona Ctr Clin Res, Altoona Arthrit Osteoporosis Ctr, Duncansville, PA USA
[2] Aurora Rheumatol & Immunotherapy Ctr, Dept Rheumatol, Franklin, WI USA
[3] Quantum Res, Med, Las Lagos, Chile
[4] Ctr Rheumatol & Bone Res, Rheumatol, Wheaton, MD USA
[5] George Washington Univ, Rheumatol, Washington, DC USA
[6] Queen Elizabeth Hosp, Dept Rheumatol, Woodville, SA, Australia
[7] Basil Hetzel Inst, Rheumatol Res Grp, Woodville, SA, Australia
[8] Univ Adelaide, Adelaide Med Sch, Rheumatol, Adelaide, SA, Australia
[9] AbbVie Inc, Immunol, N Chicago, IL USA
[10] UCLouvain St Luc, Inst Rech Experimentale & Clin Univ St Luc, Brussels, Belgium
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2022年 / 81卷
关键词：
D O I：
10.1136/annrheumdis-2022-eular.1819
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
POS0685
引用
收藏
页码：620 / 621
页数：2
相关论文
共 50 条
  • [41] Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: results from the DAYBREAK open-label extension study
    Steinman, L.
    Comi, G.
    Bar-Or, A.
    Selmaj, K. W.
    Arnold, D. L.
    Hartung, H. -P.
    Montalban, X.
    Havrdova, E. K.
    Sheffield, J. K.
    Minton, N.
    Janjua, A.
    Huang, V.
    Silva, D.
    Kappos, L.
    Cohen, J. A.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 548 - 549
  • [42] Long-term efficacy and safety of omalizumab for nasal polyposis in an open-label extension study
    Gevaert, Philippe
    Saenz, Rebecca
    Corren, Jonathan
    Han, Joseph K.
    Mullol, Joaquim
    Lee, Stella E.
    Ow, Randall A.
    Zhao, Rui
    Howard, Monet
    Wong, Kit
    Islam, Lutaf
    Ligueros-Saylan, Monica
    Omachi, Theodore A.
    Bachert, Claus
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2022, 149 (03) : 957 - +
  • [43] Long-term safety and efficacy of erenumab in patients with chronic migraine: Results from a 52-week, open-label extension study
    Tepper, Stewart J.
    Ashina, Messoud
    Reuter, Uwe
    Brandes, Jan Lewis
    Dolezil, David
    Silberstein, Stephen D.
    Winner, Paul
    Zhang, Feng
    Cheng, Sunfa
    Mikol, Daniel D.
    CEPHALALGIA, 2020, 40 (06) : 543 - 553
  • [44] Long-term open-label preliminary study of the safety and efficacy of leflunomide in patients with polyarticular-course juvenile rheumatoid arthritis
    Silverman, E
    Spiegel, L
    Hawkins, D
    Petty, R
    Goldsmith, D
    Schanberg, L
    Duffy, C
    Howard, P
    Strand, V
    ARTHRITIS AND RHEUMATISM, 2005, 52 (02): : 554 - 562
  • [45] Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study
    Tanaka, Yoshiya
    Yamamoto, Kazuhiko
    Takeuchi, Tsutomu
    Yamanaka, Hisashi
    Ishiguro, Naoki
    Eguchi, Katsumi
    Watanabe, Akira
    Origasa, Hideki
    Shoji, Toshiharu
    Miyasaka, Nobuyuki
    Koike, Takao
    MODERN RHEUMATOLOGY, 2014, 24 (05) : 725 - 733
  • [46] Baricitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Rheumatoid Arthritis: 52 Week Safety and Efficacy in an Open-Label, Long-Term Extension Study
    Baker, Milton
    Chalabi, Youb
    Genovese, Mark
    Taylor, Peter
    Schlichting, Douglas
    Beattie, Scott
    Macias, William
    Keystone, Edward
    JOURNAL OF RHEUMATOLOGY, 2014, 41 (07) : 1505 - 1505
  • [47] Long-term Safety and Efficacy of Etanercept in Patients With Psoriasis: An Open-label Study
    Leonardi, Craig
    Strober, Bruce
    Gottlieb, Alice B.
    Elewski, Boni E.
    Ortonne, Jean-Paul
    van de Kerkhof, Peter
    Chiou, Chiun-Fang
    Dunn, Meleana
    Jahreis, Angelika
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : 928 - 937
  • [48] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Ruediger B. Mueller
    Hendrik Schulze-Koops
    Daniel E. Furst
    Stanley B.  Cohen
    Kenneth Kwok
    Lisy Wang
    Tim Killeen
    Johannes von Kempis
    Clinical Rheumatology, 2022, 41 : 1045 - 1055
  • [49] EVALUATION OF RESPONSE TO PNEUMOCOCCAL VACCINATION IN PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB: RESULTS FROM A PHASE 2 OPEN-LABEL EXTENSION STUDY
    Winthrop, K.
    Ignacio Vargas, J.
    Drescher, E.
    Garcia Garcia, C.
    Friedman, A.
    Enejosa, J.
    Khan, N.
    Li, Y.
    Klaff, J.
    Kivitz, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 486 - 487
  • [50] Effect of dose adjustments on the efficacy and safety of tofacitinib in patients with rheumatoid arthritis: a post hoc analysis of an open-label, long-term extension study (ORAL Sequel)
    Mueller, Ruediger B.
    Schulze-Koops, Hendrik
    Furst, Daniel E.
    Cohen, Stanley B.
    Kwok, Kenneth
    Wang, Lisy
    Killeen, Tim
    von Kempis, Johannes
    CLINICAL RHEUMATOLOGY, 2022, 41 (04) : 1045 - 1055
12345